Fast Facts: Cutaneous T-cell Lymphoma


Book Description

Cutaneous T-cell lymphoma (CTCL) has been described as a 'great mimicker'. The correct diagnosis hinges on effective collaboration between clinicians and pathologists to correlate pathological and clinical findings. The patient's history, lesion description and diagnostic work-up will help the pathologist interpret the histopathology, whilst the clinician’s diagnosis is aided by a clear understanding the terminology used in the pathology report. The treatment of early and advanced mycosis fungoides and its variants is potentially lifelong, with patients typically cycling among treatments, interspersed with periods of expectant therapy providing palliation and symptomatic relief. Effective management requires knowledge of the wide range of options, how they are used, and their side-effect profile, in order to tailor treatment to the individual patient. ' Fast Facts: Cutaneous T-Cell Lymphoma' is designed to help primary care providers, dermatologists, and oncologists to communicate effectively with pathologists in the diagnosis of this chronic condition, aided by over 100 superb clinical and pathological images, and to provide tailored long-term care for their patients. This concise, practical handbook will ensure clear communication with respect to the clinical presentation, histopathology, immunophenotyping and treatment of: • early and advanced mycosis fungoides and its variants • Sézary syndrome • other non-mycosis fungoides CTCLs. It is essential reading for pathologists, non-specialist clinicians and dermatology and oncology trainees.




Fast Facts: Lymphoma


Book Description

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.




Fast Facts: Peripheral T-cell Lymphoma


Book Description

The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.




The Peripheral T-Cell Lymphomas


Book Description

THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice.




Fast Facts: Peripheral T-cell Lymphoma


Book Description

The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.




Living with Lymphoma


Book Description

The second edition of this award-winning guide reflects profound shifts in the lymphoma landscape, including new treatments that are extending survival. Winner, American Medical Writers Association Medical Book Award When neurobiologist Elizabeth M. Adler was diagnosed with non-Hodgkin lymphoma almost twenty years ago, she learned everything she could about the disease, both to cope with the emotional stress of her diagnosis and to make the best possible decisions for her treatment. In Living with Lymphoma, she combines her scientific expertise and personal knowledge with a desire to help other people who have lymphoma manage this complex and often baffling disease. With the availability of more effective treatment regimens, many people with lymphoma are living longer; in fact, there are more than 700,000 lymphoma survivors in the United States alone. Given this change in the lymphoma landscape, the second edition of this book places a greater emphasis on survivorship. The new edition includes the latest information on lymphoma diagnosis, treatment, and incidence and describes the most recent update to the WHO system of lymphoma classification and staging. Adler discusses new targeted therapies like ibrutinib and idelalisib and describes how other treatments, including radiation therapy and stem cell transplants, have been modified while others have been discontinued. She also addresses new developments, such as the possible role of lack of sunlight and vitamin D in the pathogenesis of lymphoma, and the use of medical marijuana. The book includes suggestions for further reading, including the latest material available online.




Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma


Book Description

Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities




Hematology


Book Description




Fast Facts: Marginal Zone Lymphoma


Book Description

'Fast Facts: Marginal Zone Lymphoma' provides an overview of MZL for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the R/R setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.




Diagnosis of Cutaneous Lymphoid Infiltrates


Book Description

This volume is the first of its kind to emphasize the visual approach in the diagnosis of cutaneous lymphoid infiltrates. Written and designed in an accessible yet highly detailed format by an expert in the field, this book bridges the knowledge gaps so often found when dealing with skin lymphomas. Complete with more than two hundred high quality images and illustrations, Diagnosis of Cutaneous Lymphoid Infiltrates offers pearls and pitfalls as well as differential diagnoses. Additionally, images are explained and decoded with the use of illustrations and analogies, proving to be an invaluable resource for pathologists, dermatologists, dermatopathologists, hematopathologists, and residents and fellows in these fields.